Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1061-1080 of 3,900 trials

Mantle-Cell Lymphoma: Glofitamab with Venetoclax and Zanubrutinib

We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.

Mantle-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ALK Positive Non-Small Cell Lung Cancer: Chemotherapy Plus Lorlatinib

We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

Metastatic Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Glioblastoma: [177Lu]Lu-DOTA-TATE Treatment Study

We are exploring a new drug for patients with newly diagnosed glioblastoma alongside standard care, and for those with recurrent glioblastoma as a single treatment. The goal is to find the best dose for effective treatment.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Familial Mediterranean Fever: On-Demand Anakinra Treatment

We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.

Familial Mediterranean Fever>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious DiseasesInternal MedicineRheumatology

Penile Cancer: Carboplatin, Paclitaxel, and Pembrolizumab Study

We are studying a combination of chemotherapy and immunotherapy for patients with locoregionally advanced penile cancer. The goal is to see if this treatment can effectively shrink tumors before surgery and to assess its safety.

Locoregionally Advanced Penile Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Gastric Cancer: EXL01 with Nivolumab and FOLFOX

We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.

Metastatic Gastric Adenocarcinoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Advanced Solid Tumors: AZD3470 Study

We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.

Advanced Metastatic Solid Tumors (MTAP Deficient)Safety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: STX-721/PFL-721 Treatment

We are studying a new treatment for people with non-small cell lung cancer who have specific mutations. The goal is to see if it can improve their condition compared to standard therapies.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Spinal Muscular Atrophy: RO7204239 with Risdiplam

We are studying the safety and effectiveness of a new treatment combining RO7204239 with risdiplam for individuals with spinal muscular atrophy. This trial will help us understand how well this combination works compared to a placebo.

Spinal Muscular Atrophy (SMA)1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessPartially RemoteInternal MedicineNeurology

Ulcerative Colitis: TAK-279 Oral Medication

We are testing the effectiveness of TAK-279 for people with moderately to severely active ulcerative colitis. The study aims to see if it helps achieve remission and improves symptoms compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Lung Cancer: Selpercatinib Study

We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.

RET Fusion-Positive Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Pulmonary Hypertension: Long-term Safety Study

We are evaluating the long-term safety of treatments for pulmonary hypertension in participants who have previously received these interventions. This study aims to ensure ongoing safety for those already involved in related research.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Adrenomyeloneuropathy: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve symptoms in patients with adrenomyeloneuropathy compared to a placebo. The trial also looks at the safety of this medication.

Adrenomyeloneuropathy>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Pain Relief for Kids: Fentanyl vs. Ketamine vs. Morphine

We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.

Limb InjuriesUrgency>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Neurodegenerative Disease: Continued Access to Latozinemab

We are offering ongoing access to the medication latozinemab for individuals with neurodegenerative diseases who have participated in earlier studies. The trial will monitor safety and any clinical benefits from continued treatment.

Neurodegenerative DisordersConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

LSTA1 for Newly Diagnosed Glioblastoma Multiforme

We are studying whether adding LSTA1 to standard treatment (temozolomide) improves survival for patients with newly diagnosed GBM compared to a placebo. The trial also looks at quality of life and other important health measures.

Glioblastoma Multiforme>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

Prostate Cancer: Intermittent vs. Continuous Hormone Therapy

We are studying whether intermittent hormone therapy can maintain effectiveness and improve daily life for men with advanced prostate cancer. This trial compares it to continuous hormone therapy to see which is better for patients.

Hormone-sensitive Metastatic Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

CP-506 for Solid Tumors: A New Treatment Study

We are testing a new drug, CP-506, in patients with specific solid tumors to see how safe it is and how well it works. This study may help those with tumors that have certain genetic features or who are not responding well to current treatments.

Solid Tumors with DNA Repair Deficiencies>2 yearsSafety phase (I)Efficacy phase (II)Oncology